News from Mylan, Sigma-Tau and Immunocore – People on the move
We begin this week with news from Mylan who has appointed Deborah Autor as Senior VP of Strategic Global Quality and Regulatory Policy.
Autor has spent the last 11 years working for the US Food and Drug Administration (FDA), most recently as deputy commissioner for Global Regulatory Operations and Policy where she led the implementation of the FDA's strategy for addressing the challenges of globalization and import safety.
Mylan’s CEO Heather Bresch said: “Deb's insights into the challenges of globalization to the health care sector will be extremely valuable as we continue to seek to raise the bar on quality standards for the industry around the world.”
And earlier this year, Mylan splashed out $1.6bn to buy injectables company Agila. Read about it here.
Next up and there is a new position at Sigma-Tau Pharmaceuticals in the form of CEO and the company has pulled up Dave Lemus from his role as COO to fill it.
Lemus joined the Company as Vice President of Finance in July 2011 and rose to COO nine months later. Prior to working at Sigma-Tau, he was Executive VP and CFO of MorphoSys AG, and before this he has worked at Hoffmann La Roche and Lindt Chocolate.
Regarding Lemus’ promotion, company President Prof. Trevor Jones said: “His appointment comes at a pivotal time in the development of the Company, as it now expands via commercialization of its proprietary internal R&D pipeline, and the pursuit of externally driven growth opportunities.”
Oxford, UK-based biotech firm Immunocore Ltd has appointed Eva-Lotta Allan to the Board as Chief Business Officer.
Allan has over twenty years of experience in the biotech and life science industries and comes direct from Ablynx where she has been Chief Business Officer since 2006.
According to Immunocore’s CEO James Noble, Allan “brings with her a wealth of knowledge and experience in business development” as the company expands and develops its product pipeline.
Next up is clinical stage biopharmaceutical company VentiRx Pharmaceuticals who has announced the appointment of Dr. James Kyle Bryan as Chief Medical Officer.
With over 20 years of oncology drug discovery and development experience, Bryan “will be invaluable to VentiRx going forward” according to the company’s CEO Dr. Robert Hershberg. He added: “Kyle will be integral in directing our clinical development efforts.”
Bryan’s previous role was Vice President of Global Product Development at PPD, a CRO who last month bolstered its services in the US and Brazil. Read the story here.
Finally for this week, Wendy Yarno has been elected to the Board of Directors at biopharma company Medivation.
Yarno has spent over 26 years in various executive roles at Merck & Co. (known as MSD outside North America), retiring from her most recent role of Chief Marketing Officer in 2008.
Medivation’s President and CEO Dr. David Hung welcomed Yarno, adding: “Wendy is an accomplished executive and her unique mix of experience in both the commercialization of pharmaceutical products and human resources management makes her an excellent addition to our board of directors.”